They showed that 250 μg/mouse of an anti-murine TIM-3 antibody given at day 7, 11, and 15 post intracranial implantation of GL261 mouse glioma cells had no significant effect to mouse median or overall survival (OS) compared to control treated mice. The gene discussed is HAVCR2; the disease is central nervous system cancer.